<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Russian Journal of Oncology</journal-id><journal-title-group><journal-title xml:lang="en">Russian Journal of Oncology</journal-title><trans-title-group xml:lang="ru"><trans-title>Российский онкологический журнал</trans-title></trans-title-group></journal-title-group><issn publication-format="print">1028-9984</issn><issn publication-format="electronic">2412-9119</issn><publisher><publisher-name xml:lang="en">Eco-Vector</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">633385</article-id><article-id pub-id-type="doi">10.17816/onco633385</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Original Study Articles</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Оригинальные исследования</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Differential cytological diagnosis of typical and atypical lung carcinoids</article-title><trans-title-group xml:lang="ru"><trans-title>Дифференциальная цитологическая диагностика типичного и атипичного карциноида лёгкого</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-9981-2348</contrib-id><contrib-id contrib-id-type="spin">7250-6259</contrib-id><name-alternatives><name xml:lang="en"><surname>Grigoruk</surname><given-names>Olga G.</given-names></name><name xml:lang="ru"><surname>Григорук</surname><given-names>Ольга Григорьевна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Dr. Sci. (Biology), Professor</p></bio><bio xml:lang="ru"><p>доктор биол. наук, профессор</p></bio><email>cytolakod@rambler.ru</email><xref ref-type="aff" rid="aff1"/><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-3290-7187</contrib-id><name-alternatives><name xml:lang="en"><surname>Vikhlyanov</surname><given-names>Igor V.</given-names></name><name xml:lang="ru"><surname>Вихлянов</surname><given-names>Игорь Владиславович</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, Dr. Sci. (Medicine), Professor</p></bio><bio xml:lang="ru"><p>доктор мед.наук, профессор</p></bio><email>akod@zdravalt.ru</email><xref ref-type="aff" rid="aff1"/><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-4925-1938</contrib-id><contrib-id contrib-id-type="spin">6603-9568</contrib-id><name-alternatives><name xml:lang="en"><surname>Tsoy</surname><given-names>Dmitrii  A.</given-names></name><name xml:lang="ru"><surname>Цой</surname><given-names>Дмитрий Александрович</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD</p></bio><email>dimazeu@gmail.com</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-7222-0657</contrib-id><name-alternatives><name xml:lang="en"><surname>Bazulina</surname><given-names>Larisa M.</given-names></name><name xml:lang="ru"><surname>Базулина</surname><given-names>Лариса Михайловна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD</p></bio><email>lardoc69@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Altai Regional Oncological Dispensary</institution></aff><aff><institution xml:lang="ru">Алтайский краевой онкологический диспансер</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">Kemerovo State Medical University</institution></aff><aff><institution xml:lang="ru">Кемеровский государственный медицинский университет</institution></aff></aff-alternatives><pub-date date-type="preprint" iso-8601-date="2024-11-20" publication-format="electronic"><day>20</day><month>11</month><year>2024</year></pub-date><pub-date date-type="pub" iso-8601-date="2024-12-20" publication-format="electronic"><day>20</day><month>12</month><year>2024</year></pub-date><volume>29</volume><issue>2</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>93</fpage><lpage>103</lpage><history><date date-type="received" iso-8601-date="2024-06-10"><day>10</day><month>06</month><year>2024</year></date><date date-type="accepted" iso-8601-date="2024-11-09"><day>09</day><month>11</month><year>2024</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2024, Eco-Vector</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2024, Эко-Вектор</copyright-statement><copyright-year>2024</copyright-year><copyright-holder xml:lang="en">Eco-Vector</copyright-holder><copyright-holder xml:lang="ru">Эко-Вектор</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/" start_date="2027-12-20"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by-nc-nd/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://rjonco.com/1028-9984/article/view/633385">https://rjonco.com/1028-9984/article/view/633385</self-uri><abstract xml:lang="en"><p><bold><italic>Background</italic></bold><bold><italic>:</italic></bold><bold> </bold>The potential for diagnosing lung carcinoids using cytological methods has been underexplored, with limited publications available to support evidence-based conclusions.</p> <p><bold><italic>Aim</italic></bold><bold><italic>:</italic></bold> This study aims to evaluate the of cytological diagnostic capabilities for differentiating typical and atypical lung carcinoids.</p> <p><bold><italic>Materials</italic></bold><bold><italic> and Methods:</italic></bold> The study included cytological examination results from 18 patients diagnosed with <italic>carcinoid tumor</italic> at the cytological laboratory of the Altai Regional Oncology Dispensary (Barnaul). The cell material of carcinoid tumors was obtained during diagnostic video bronchoscopy and stained using the Pappenheim method. In all observations, the final diagnosis was the result of histological examination of tumors with immunohistochemical reactions. The obtained results were evaluated using Microsoft Office Excel 2010 and Statistica 10.0. Significant cellular signs (using multivariate analysis) were determined which were assessed to solve diagnostic problems when establishing a cytological diagnosis. Differences between carcinoids were assessed using discriminant analysis with Fisher’s F-test.</p> <p><bold><italic>Results</italic></bold><bold><italic>:</italic></bold> Carcinoid tumors accounted for 2.72% of the number of neuroendocrine lung neoplasms. Typical carcinoid was diagnosed in 13 patients, atypical carcinoid was observed in 5 cases. The average age at onset of typical carcinoid was 58.46±19.04 years, of atypical carcinoid — 63.2±4.66 years. Cellular features of typical and atypical carcinoids were assessed, which formed the basis for the statistical analysis. To identify the most informative combinations of cellular features, a multivariate analysis was used that determined the main cytological features for carcinoids characterization, using only light microscopy. The values of the first, second, and third factors were determined; the factor value of the cellular feature variants was 96.02% of the sample (variance). In the discriminant analysis, 14 initial tumor cell parameters (discriminant indices) were used to classify patients into one of two groups (typical and atypical carcinoids), on the basis of which the results of the carcinoid study were classified. Step-by-step assessment using Fisher’s F-test revealed differences that amounted to 37.97% only, suggesting that the cellular features are statistically insignificant.</p> <p><bold><italic>Conclusion</italic></bold><bold><italic>:</italic></bold><bold> </bold>The data obtained demonstrate the possibilities of cytological diagnosis of lung carcinoids using only light microscopy at the first stage of patient examination. Cellular features enable to diagnose the <italic>carcinoid tumor</italic> with an accuracy of more than 96%. However, it is possible to differentiate between typical and atypical carcinoids in less than 40% of cases due to the large number of similar features.</p></abstract><trans-abstract xml:lang="ru"><p><bold>Обоснование. </bold>В настоящее время немногочисленные публикации по возможности диагностики карциноидов лёгкого цитологическим методом не достаточны для доказательных выводов.</p> <p><bold>Цель.</bold> Оценить возможности цитологической диагностики дифференцирования типичного и атипичного карциноидов лёгкого.</p> <p><bold>Материалы и методы. </bold>В исследование вошли результаты цитологического обследования 18 пациентов с заключением «карциноидная опухоль», которые были диагностированы в цитологической лаборатории Алтайского краевого онкологического диспансера (г. Барнаул). Клеточный материал карциноидных опухолей был получен при диагностической видеобронхоскопии. Препараты окрашивали по Паппенгейму. Во всех наблюдениях окончательным диагнозом были результаты гистологического исследования опухолей с проведением иммуногистохимических реакций. Для оценки полученных результатов использовали программы Microsoft Office Excel 2010 и Statistica 10.0. Определяли значимые клеточные признаки (многофакторный анализ), которые оценивали для решения диагностических задач при установлении цитологического диагноза. Различия между карциноидами оценивали с применением дискриминантного анализа с использованием F-критерий Фишера.</p> <p><bold>Результаты.</bold> Карциноидные опухоли составили 2,72% от числа нейроэндокринных новообразований лёгких. Типичный карциноид диагностирован у 13 пациентов, атипичный отмечен в 5 случаях. Средний возраст при развитии типичного карциноида составил 58,46±19,04 года, при атипичном карциноиде — 63,20±4,66 года. Оценены клеточные признаки типичного и атипичного карциноидов, которые стали основой для статистического анализа. Для выделения наиболее информативных комбинаций клеточных признаков применён многофакторный анализ, который определил основные цитологические признаки для характеристики карциноидов, используя только световую микроскопию. Определены значения первого, второго и третьего факторов: факторный вес вариантов клеточных признаков составил 96,02% выборки (дисперсии). При дискриминантном анализе для отнесения пациентов к одной из двух групп (типичного или атипичного карциноидов) использованы 14 исходных показателей клеток опухоли (дискриминантные индексы), по которым классифицировали результаты исследования карциноидов. При пошаговой оценке с использованием F-критерия Фишера определены различия, которые составили только 37,97%, что свидетельствует о том, что клеточные признаки статистически не значимы.</p> <p><bold>Заключение. </bold>Полученные данные демонстрируют возможности цитологической диагностики карциноидов лёгкого, используя только световую микроскопию, на первом этапе обследования пациентов. Клеточные признаки позволяют сделать заключение «карциноидная опухоль» с точностью более 96%. Однако дифференцировать типичный и атипичный карциноиды возможно менее чем в 40% наблюдений ввиду большого числа однотипных признаков.</p></trans-abstract><kwd-group xml:lang="en"><kwd>typical carcinoid</kwd><kwd>atypical carcinoid</kwd><kwd>cytological diagnosis</kwd><kwd>light microscopy</kwd><kwd>multivariate analysis</kwd><kwd>discriminant analysis</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>типичный карциноид</kwd><kwd>атипичный карциноид</kwd><kwd>цитологическая диагностика</kwd><kwd>световая микроскопия</kwd><kwd>многофакторный анализ</kwd><kwd>дискриминантный анализ</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><citation-alternatives><mixed-citation xml:lang="en">WHO Classification of Tumours Editorial Board. WHO Classification of Tumours, 5th Edition, Volume 5. Thoracic tumours. Lyon: International Agency for Research on Cancer; 2021.</mixed-citation><mixed-citation xml:lang="ru">WHO Classification of Tumours Editorial Board. WHO Classification of Tumours, 5th Edition, Volume 5. Thoracic tumours. Lyon : International Agency for Research on Cancer, 2021.</mixed-citation></citation-alternatives></ref><ref id="B2"><label>2.</label><citation-alternatives><mixed-citation xml:lang="en">Metovic J, Barella M, Bianchi F, et al. Morphologic and molecular classification of lung neuroendocrine neoplasms. Virchows Arch. 2021;478(1):5–19. doi: 10.1007/s00428-020-03015-z</mixed-citation><mixed-citation xml:lang="ru">Metovic J., Barella M., Bianchi F., et al. Morphologic and molecular classification of lung neuroendocrine neoplasms // Virchows Arch. 2021. Vol. 478, N 1. P. 5–19. doi: 10.1007/s00428-020-03015-z</mixed-citation></citation-alternatives></ref><ref id="B3"><label>3.</label><citation-alternatives><mixed-citation xml:lang="en">Faggiano A, Ferolla P, Grimaldi F, et al. Natural history of gastro-entero-pancreatic and thoracic neuroendocrine tumors. Data from a large prospective and retrospective Italian epidemiological study: the NET management study. J Endocrinol Invest. 2012;35(9):817–823. doi: 10.3275/8102</mixed-citation><mixed-citation xml:lang="ru">Faggiano A., Ferolla P., Grimaldi F., et al. Natural history of gastro-entero-pancreatic and thoracic neuroendocrine tumors. Data from a large prospective and retrospective Italian epidemiological study: the NET management study // J Endocrinol Invest. 2012. Vol. 35, N 9. P. 817–823. doi: 10.3275/8102</mixed-citation></citation-alternatives></ref><ref id="B4"><label>4.</label><citation-alternatives><mixed-citation xml:lang="en">McCaughan BC, Martini N, Bains MS. Bronchial carcinoids. Review of 124 cases. J Thorac Cardiovasc Surg. 1985;89(1):8–17.</mixed-citation><mixed-citation xml:lang="ru">McCaughan B.C., Martini N., Bains M.S. Bronchial carcinoids. Review of 124 cases // J Thorac Cardiovasc Surg. 1985. Vol. 89, N 1. P. 8–17.</mixed-citation></citation-alternatives></ref><ref id="B5"><label>5.</label><citation-alternatives><mixed-citation xml:lang="en">Halperin DM, Shen C, Dasari A, et al. Frequency of carcinoid syndrome at neuroendocrine tumour diagnosis: a population-based study. Lancet Oncol. 2017;18(4):525–534. doi: 10.1016/S1470-2045(17)30110-9</mixed-citation><mixed-citation xml:lang="ru">Halperin D.M., Shen C., Dasari A., et al. Frequency of carcinoid syndrome at neuroendocrine tumour diagnosis: a population-based study // Lancet Oncol. 2017. Vol. 18, N 4. P. 525–534. doi: 10.1016/S1470-2045(17)30110-9</mixed-citation></citation-alternatives></ref><ref id="B6"><label>6.</label><citation-alternatives><mixed-citation xml:lang="en">Trevis WD, Brambilla E, Burke AP, et al. WHO Classification of Tumours of the Lung, Pleura, Thymus and Heart. 4th ed. Lyon: IARC; 2015.</mixed-citation><mixed-citation xml:lang="ru">Trevis W.D., Brambilla E., Burke A.P., et al. WHO Classification of Tumours of the Lung, Pleura, Thymus and Heard. 4th ed. Lyon : IARC, 2015.</mixed-citation></citation-alternatives></ref><ref id="B7"><label>7.</label><citation-alternatives><mixed-citation xml:lang="en">Melosky B. Low Grade Neuroendocrine Tumors of the Lung. Front Oncol. 2017;7:119. doi: 10.3389/fonc.2017.00119</mixed-citation><mixed-citation xml:lang="ru">Melosky B. Low Grade Neuroendocrine Tumors of the Lung // Front Oncol. 2017. Vol. 7. P. 119. doi: 10.3389/fonc.2017.00119</mixed-citation></citation-alternatives></ref><ref id="B8"><label>8.</label><citation-alternatives><mixed-citation xml:lang="en">Riihimaki M, Hemminki A, Sundquist K, et al. The epidemiology of metastases in neuroendocrine tumors. Int J. Cancer. 2016;139:2679–2686. doi: 10.1002/ijc.30400</mixed-citation><mixed-citation xml:lang="ru">Riihimaki M., Hemminki A., Sundquist K., et al. The epidemiology of metastases in neuroendocrine tumors // Int J. Cancer. 2016. Vol. 139. P. 2679–2686. doi: 10.1002/ijc.30400</mixed-citation></citation-alternatives></ref><ref id="B9"><label>9.</label><citation-alternatives><mixed-citation xml:lang="en">Travis WD. Pathology and diagnosis of neuroendocrine tumors: lung neuroendocrine. Thorac Surg Clin. 2014;24(3):257–266. doi: 10.1016/j.thorsurg.2014.04.001</mixed-citation><mixed-citation xml:lang="ru">Travis W.D. Pathology and diagnosis of neuroendocrine tumors: lung neuroendocrine // Thorac Surg Clin. 2014. Vol. 24, N 3. P. 257–266. doi: 10.1016/j.thorsurg.2014.04.001</mixed-citation></citation-alternatives></ref><ref id="B10"><label>10.</label><citation-alternatives><mixed-citation xml:lang="en">Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70(1):7–30. doi: 10.3322/caac.21590</mixed-citation><mixed-citation xml:lang="ru">Siegel R.L., Miller K.D., Jemal A. Cancer statistics, 2020 // CA Cancer J Clin. 2020. Vol. 70, N 1. P. 7–30. doi: 10.3322/caac.21590</mixed-citation></citation-alternatives></ref><ref id="B11"><label>11.</label><citation-alternatives><mixed-citation xml:lang="en">Rindi G, Klimstra DS, Abedi-Ardekani B, et al. A common classification framework for neuroendocrine neoplasms: an International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert consensus proposal. Mod Pathol. 2018;31(12):1770–1786. doi: 10.1038/s41379-018-0110-y</mixed-citation><mixed-citation xml:lang="ru">Rindi G., Klimstra D.S., Abedi-Ardekani B., et al. A common classification framework for neuroendocrine neoplasms: an International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert consensus proposal // Mod Pathol. 2018. Vol. 31, N 12. P. 1770–1786. doi: 10.1038/s41379-018-0110-y</mixed-citation></citation-alternatives></ref><ref id="B12"><label>12.</label><citation-alternatives><mixed-citation xml:lang="en">Caplin ME, Baudin E, Ferolla P, et al. Pulmonary neuroendocrine (carcinoid) tumors: European Neuroendocrine Tumor Society expert consensus and recommendations for best practice for typical and atypical pulmonary carcinoids. Ann Oncol. 2015;26(8):1604–1620. doi: 10.1093/annonc/mdv041</mixed-citation><mixed-citation xml:lang="ru">Caplin M.E., Baudin E., Ferolla P., et al. Pulmonary neuroendocrine, N carcinoid) tumors: European Neuroendocrine Tumor Society expert consensus and recommendations for best practice for typical and atypical pulmonary carcinoids // Ann Oncol. 2015. Vol. 26, N 8. P. 1604–1620. doi: 10.1093/annonc/mdv041</mixed-citation></citation-alternatives></ref><ref id="B13"><label>13.</label><citation-alternatives><mixed-citation xml:lang="en">Rooper LM, Sharma R, Li QK, Illei PB, Westra WH. INSM1 Demonstrates Superior Performance to the Individual and Combined Use of Synaptophysin, Chromogranin and CD56 for Diagnosing Neuroendocrine Tumors of the Thoracic Cavity. Am J Surg Pathol. 2017;41(11):1561–1569. doi: 10.1097/PAS.0000000000000916</mixed-citation><mixed-citation xml:lang="ru">Rooper L.M., Sharma R., Li Q.K., Illei P.B., Westra W.H. INSM1 Demonstrates Superior Performance to the Individual and Combined Use of Synaptophysin, Chromogranin and CD56 for Diagnosing Neuroendocrine Tumors of the Thoracic Cavity // Am J Surg Pathol. 2017. Vol. 41, N 11. P. 1561–1569. doi: 10.1097/PAS.0000000000000916</mixed-citation></citation-alternatives></ref><ref id="B14"><label>14.</label><citation-alternatives><mixed-citation xml:lang="en">Fujino K, Motooka Y, Hassan WA, et al. Insulinoma-Associated Protein 1 Is a Crucial Regulator of Neuroendocrine Differentiation in Lung Cancer. Am J Pathol. 2015;185(12):3164–3177. doi: 10.1016/j.ajpath.2015.08.018</mixed-citation><mixed-citation xml:lang="ru">Fujino K., Motooka Y., Hassan W.A., et al. Insulinoma-Associated Protein 1 Is a Crucial Regulator of Neuroendocrine Differentiation in Lung Cancer // Am J Pathol. 2015. Vol. 185, N 12. P. 3164–3177. doi: 10.1016/j.ajpath.2015.08.018</mixed-citation></citation-alternatives></ref><ref id="B15"><label>15.</label><citation-alternatives><mixed-citation xml:lang="en">Walts AE, Ines D, Marchevsky AM. Limited role of Ki-67 proliferative index in predicting overall short-term survival in patients with typical and atypical pulmonary carcinoid tumors. Mod Pathol. 2012;25(9):1258–1264. doi: 10.1038/modpathol.2012.81</mixed-citation><mixed-citation xml:lang="ru">Walts A.E., Ines D., Marchevsky A.M. Limited role of Ki-67 proliferative index in predicting overall short-term survival in patients with typical and atypical pulmonary carcinoid tumors // Mod Pathol. 2012. Vol. 25, N 9. P. 1258–1264. doi: 10.1038/modpathol.2012.81</mixed-citation></citation-alternatives></ref><ref id="B16"><label>16.</label><citation-alternatives><mixed-citation xml:lang="en">Swarts DR, Rudelius M, Claessen SM, et al. Limited additive value of the Ki-67 proliferative index on patient survival in World Health Organization-classified pulmonary carcinoids. Histopathology. 2017;70(3):412–422. doi: 10.1111/his.13096</mixed-citation><mixed-citation xml:lang="ru">Swarts D.R., Rudelius M., Claessen S.M., et al. Limited additive value of the Ki-67 proliferative index on patient survival in World Health Organization-classified pulmonary carcinoids // Histopathology. 2017. Vol. 70, N 3. P. 412–422. doi: 10.1111/his.13096</mixed-citation></citation-alternatives></ref><ref id="B17"><label>17.</label><citation-alternatives><mixed-citation xml:lang="en">Marchiò C, Gatti G, Massa F, et al. Distinctive pathological and clinical features of lung carcinoids with high proliferation index. Virchows Arch. 2017;471(6):713–720. doi: 10.1007/s00428-017-2177-0</mixed-citation><mixed-citation xml:lang="ru">Marchiò C., Gatti G., Massa F., et al. Distinctive pathological and clinical features of lung carcinoids with high proliferation index // Virchows Arch. 2017. Vol. 471, N 6. P. 713–720. doi: 10.1007/s00428-017-2177-0</mixed-citation></citation-alternatives></ref></ref-list></back></article>
